Intellia Therapeutics, Inc. (NTLA)
Nasdaq: NTLA · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA · filing with the SEC since 2015
The company now
Intellia Therapeutics, Inc. is classed by the SEC under In Vitro & In Vivo Diagnostic Substances (industry code 2835), based in Cambridge, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $68 million and a loss of $413 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
The desk's written account, its read of the annual report, the record in brief and the split of the revenue are not on file for this company yet.